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Abstract: A critical first step in a “rational vaccine design” approach for hepatitis C virus 
(HCV) is to identify the most relevant mechanisms of immune protection. Emerging 
evidence provides support for a protective role of virus neutralizing antibodies, and the 
ability of the B cell response to modify the course of acute HCV infection. This has been 
made possible by the development of in vitro cell culture models, based on HCV retroviral 
pseudotype particles expressing E1E2 and infectious cell culture-derived HCV virions, and 
small animal models that are robust tools in studies of antibody-mediated virus 
neutralization. This review is focused on the immunogenic determinants on the E2 
glycoprotein mediating virus neutralization and the pathways in which the virus is able to 
escape from immune containment. Encouraging findings from recent studies provide 
support for the existence of broadly neutralization antibodies that are not associated with 
virus escape. The identification of conserved epitopes mediating virus neutralization that 
are not associated with virus escape will facilitate the design of a vaccine immunogen 
capable of eliciting broadly neutralizing antibodies against this highly diverse virus.  
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1. Introduction 
Up to 170 million people worldwide are chronically infected with hepatitis C virus (HCV), with 
many at significant risk for cirrhosis, liver failure and hepatocellular
 carcinoma [1]. The virus is 
transmitted primarily by parenteral routes. From unsafe needle injections alone, the World Health 
Organization estimates an annual increase in the global burden by 2 million new infections [2]. Until 
this year, treatment was primarily with pegylated-interferon and ribavirin, which helped some patients 
with chronic HCV infection. But viral replication was incompletely inhibited and a high relapse rate 
occurred when patients discontinued treatment. The recent advances in in vitro and in vivo HCV 
infection systems and increased understanding of HCV virology have led to the development of many 
HCV-specific small molecules with antiviral activity. This has led to new optimism in HCV treatment 
programs with the recent completion of Phase III studies of several protease inhibitors having 
promising results [3]. However, the potential for drug resistant HCV mutants from these direct-acting 
antivirals is an ongoing concern [4]. A vaccine-based preventive strategy is clearly needed. A critical 
first step in a “rational vaccine design” approach for HCV is to identify mechanisms of immune 
protection. The induction of neutralizing antibodies following vaccination provides a first line of 
adaptive immune defense against a number of viral pathogens. For HCV, emerging evidence indicates 
a protective role of virus neutralizing antibodies, and the ability of the B cell response to modify the 
course of infection.  
2. The Role of Neutralizing Antibodies in Controlling HCV Infection  
Virus neutralizing antibodies are an important component of protection against many viral 
pathogens. But for some viruses, such as HCV, the protective role for neutralizing antibodies is not 
readily apparent because the drop in peak viral load during acute infection is more temporally 
correlated with cellular immunity rather than the appearance of neutralizing antibodies [5,6]. CD4+ 
and CD8+ T cell responses correlate with control of acute infection, although they are not sufficient to 
prevent chronic infection and disease progression [7]. The role of antibodies in preventing and 
controlling HCV infection has been less defined because of difficulties in having efficient and reliable 
in vitro systems to grow HCV. Nonetheless, clinical trials with IgG therapy before the isolation of 
HCV demonstrated prevention of transfusion-associated non-A, non-B hepatitis that was due mostly to 
HCV [8–11]. Other clinical studies showed a reduction of infection transmission among sex partners 
of HCV-infected patients who received gammaglobulin [12]. Early animal studies supported this 
observation. An infectious inoculum obtained during acute infection from a patient who eventually 
developed chronic HCV hepatitis could be neutralized by in vitro incubation with plasma of the same 
subject collected from 2 years after infection [13]. Other early animal studies observed a delay in the 
onset of acute infection when chimpanzees were treated with HCV gammaglobulin prior to challenge 
with infectious virus [14].  
The development of in vitro cell culture models and neutralization assays, based on HCV retroviral 
pseudotype particles expressing E1E2 (HCVpp) and infectious cell culture-derived HCV virions 
(HCVcc), has facilitated the measurement of antibody-mediated virus neutralization, and thus to 
evaluate the impact of antibody in the control of infection [15–19]. This led to the observation that the 
protective effect provided by IgG preparations in chimpanzee challenged studies correlated with Viruses 2011, 3 
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antibody titers blocking infection of target cells with HCVpp [20]. Moreover, studies with retroviral 
HCVpp have shown a relationship between the control of virus infection and a neutralizing antibody 
response in single source outbreaks of acute HCV infections [21,22]. One group involved a large 
cohort of pregnant women who received anti-RhD gammaglobulin contaminated with a single 1b HCV 
strain, and the other involved hemodialysis patients with nosocomial acquired HCV infection. Both 
studies, employing HCVpp, showed a relationship between the control of virus infection and the 
neutralizing antibody response in acute HCV infections [21,22]. Individuals with a strong and 
progressive neutralizing HCVpp antibody response demonstrated decreasing viremia. Viral clearance 
was associated with a rapid induction of neutralizing antibodies in the early phase of infection with 
some evidence that these antibodies are broadly reactive [21,22]. In contrast, chronic HCV infection 
was characterized by absent or low-titer neutralizing antibodies in the early phase of infection and the 
persistence of infection despite the induction of cross-neutralizing antibodies in the late phase of 
infection. Moreover, escape from neutralizing antibodies appears to influence HCV re-infection of the 
liver graft during liver transplantation [23]. These findings suggest that the quality and quantity of the 
neutralizing antibody response during acute infection are potential determinants of infection outcome.  
Recently developed small animal models have provided additional tools to evaluate the role of 
antibodies in HCV infection and immunity. One model is based on immunodeficient mice re-populated 
with human liver fragments [24]. In a homologous in vivo protection study, chimeric mice were 
prophylactically treated with chronic phase polyclonal IgG prepared from serum of an individual with 
chronic HCV infection. The mice were then challenged with infectious virus obtained from the same 
individual during acute infection. Infection was prevented in five of eight challenged animals. For the 
non-protected animals, the HCV infection was attenuated [25]. In a study of a human monoclonal 
antibody (HMAb) that neutralized genetically diverse genotype HCVpp, prophylactic treatment 
provided protection against heterologous infectious HCV challenge in this human liver chimeric 
mouse model [26]. A more recently developed immunocompetent humanized mouse model for HCV 
exhibited a robust antibody response to vaccination with a recombinant vaccinia virus expressing HCV 
C-E1-E2-p7-NS2 proteins. Some of the vaccinated animals were protected against a heterologous 
infectious HCV challenge and protection was correlated with the serum level of antibodies to E2 [27]. 
The HCV envelope glycoproteins, E1 and E2, are the natural targets of the protective antibody 
response. The focus of this review is on the immunogenic determinants on E2 mediating virus 
neutralization. Reported E1-specific neutralizing antibodies are more limited [28,29] and probably 
reflect that this protein is of lower immunogenicity than E2. However, there is evidence that 
E1-specific responses can be invoked following experimental vaccination and these responses may be 
protective [30]. 
3. Neutralizing Antibodies to Linear Epitopes  
HCV entry into target cells requires attachment to surface glycosaminoglycans and perhaps 
lipoprotein receptors leading to the interaction of viral glycoproteins with co-receptors, CD81 and 
SR-BI. Subsequent to these events, Claudin-I, other claudin molecules, and another hepatocyte tight 
junction protein, Occludin, are felt to be involved in the entry pathway [31–36]. The envelope 
glycoproteins, E1E2, are responsible for virus attachment and receptor-mediated endocytosis. Viruses 2011, 3 
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However, there is convincing evidence of E2 binding only to CD81 and SR-B1 [37,38]. Monoclonal or 
polyclonal antibodies targeting both linear and conformational epitopes of E2 have been shown to 
mediate virus neutralization.  
A major determinant of neutralization is the “hyper-variable region 1” (HVR1), which encompass 
the first 27 amino acids (aa 384–410) located at the N-terminus of HCV E2 [13,39]. This E2 segment 
is highly immunogenic and antibodies against HVR1 can be detected in the majority of HCV infected 
individuals [40–42]. Animals immunized with synthetic HVR1 peptide elicit high titer serum 
antibodies to HVR1 [43,44]. Comparing the protective effect of HVR1 peptide with HCV E1, E2 
recombinant protein immunization, protection was more associated with anti-HVR1 antibody titers 
than with anti-E1 or anti-E2 [45–47]. However, antibodies to HVR1 over time drive replication of 
viral variants that the existing antibody response does not recognize [13,48,49]. The limited nature of 
the B cell response to this region is shown in a study of sequential HCV sequences isolated from one 
patient over a 26-year period [50]. Patient-specific HCVpp expressing sequential envelope variants 
were employed to assess virus neutralization by autologous sera. While capable of neutralizing earlier 
quasispecies, serum antibodies failed to neutralize the concurrent dominant HCV E1E2 species that 
were present in the blood. Escape was associated with mutations within HVR1 leading to decreased 
binding and neutralization by monoclonal antibodies that were produced to the earliest E2 HVR1 
sequence obtained from this patient. Another study of individuals progressing from the acute phase of 
infection to chronicity confirmed both the relationship between neutralizing antibodies and virus 
clearance, and escape from neutralization secondary to HVR1 variants [51]. High-titer serum 
neutralizing antibodies were detected in individuals with spontaneous resolution of infection, peaking 
at the time of viral clearance, while most individuals progressing to chronic infection demonstrated 
low-titer or absent neutralizing antibodies throughout early acute infection. When patient-specific 
HCVpp expressing sequential envelope variants were used to assess neutralization by autologous sera, 
neutralization of earlier sequence variants was detected prior to later variants, indicating clearance and 
evolution of quasispecies variants in response to pressure from neutralizing antibodies. Site directed 
mutagenesis of the pseudotyped envelope sequence revealed amino acid substitutions within HVR1 
that were responsible for the loss of neutralization sensitivity over time. One interpretation of these 
findings is that neutralizing antibodies directed at more conserved epitopes outside of HVR1 are likely 
to occur late in the course of disease progression, since the majority of infected individuals develop 
chronic infection. Nonetheless, for some patients, the early appearance of neutralizing antibodies 
appeared to contribute to the control of viremia. Antibodies to HVR1 are mostly isolate-specific, 
although there are reports of broadly reactive HVR1 antibodies [40,43,52,53]. Interestingly, delta 
HVR1 viral particles are more sensitive to antibody-mediated neutralization, which indicates that 
HVR1 partly shields more conserved epitopes mediating neutralization [54,55]. Taken together, these 
findings suggest that the HVR1 region encodes immunodominant epitopes that elicit neutralizing 
antibodies, and in the early acute infection these antibodies have a possible role in the resolution of 
acute infection. However, these epitopes tend to be isolate-specific and therefore are of limited utility 
in vaccine development.  
An E2 segment that is adjacent to HVR1, encompassing aa410–425, is recognized as encoding 
highly conserved neutralizing epitopes. The mouse monoclonal antibody, AP33, was the first reported 
antibody that defined a linear epitope in this region having contact residues within aa412–423 [56,57]. Viruses 2011, 3 
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The antibody displays broad neutralization against HCVpp bearing E1E2 representatives of the major 
HCV genotypes 1 through 6 [57], which is consistent with this epitope being highly conserved. Other 
monoclonal antibodies of both murine and human origins, such as 3/11, 95-2 and HCV-1, have been 
reported to bind to epitopes within aa412–423 and displaying broadly neutralizing activities [57–59]. 
Epitope mapping showed that the W420 is a conserved contact residue shared by these antibodies 
(Figure 1). W420 also serves as a critical residue for virus binding to CD81 [60]. Another murine 
monoclonal antibody, H77.39, has been described to bind to an epitope containing contact residues 
within aa410–425, at N415 and N417 [61]. Interestingly, this antibody inhibits both E2 binding to 
CD81 and SR-B1. In a proposed model of the tertiary organization of HCV E2 [62], the AP33 epitope 
is comprised of contact residues located on two -strands, B0 and C0 within domain I (Figure 2) 
(see [63] for domain and strand nomenclature). The contact residue for The AP33 epitope is mostly 
regarded as a linear epitope, but it contains a conformational component, as suggested by a modest 
reduction in AP33 binding to denatured E1E2 [56]. This was confirmed by in vitro selection of AP33 
neutralization-escape virus mutants that located an escape mutation at a considerable distance from 
aa412–423 [64]. Unlike HVR1, antibodies to the aa412–423 appear to be less prevalent and present in 
less than 2.5% of sera obtained from individuals with chronic HCV infection, and in 1 from 32 patients 
who resolved HCV infection. This finding suggests that AP33-like antibodies do not play a major role 
in natural clearance of HCV infection [65]. The 412–423 epitope also appears to be weakly 
immunogenic in the HuMAb mice (transgenic mice containing human antibody genes) immunized 
with soluble E2. Of the total 51 immunized mice, hybridomas producing antibodies reactive to this 
epitope were isolated from only two animals [58]. 
Analysis of over 5,500 sequences obtained from GenBank database showed that the AP33 epitope 
is highly conserved. In spite of this observation, escape mutations within aa412–423 have been 
documented. In the presence of AP33, a N415Y mutant arose under selection pressure. The mutant 
variant is resistant to AP33-mediated neutralization but the mutation is associated with a cost in virus 
fitness [64]. Collectively, this suggests that the AP33 epitope should be incorporated in an HCV 
vaccine. However, multiple mutations, G418D and N415D, have been reported that escape 
AP33-mediated neutralization and not associated with a lowering of virus fitness. Of note is that these 
mutations contributed to AP33-escape variants that were more sensitive to neutralization by other 
neutralizing HMAbs to E2 [66]. Viruses 2011, 3 
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Figure 1. Mapping of neutralization epitopes on the HCV E2 protein sequence. The 
alignment of the HCV gene sequence is based on the genotype 1a, H77c (GenBank 
accession no. AF011751). Regions that are associated with CD81 binding (blue square), 
HVR1 (solid brown square), transmembrane domain (TM) and glycosylation sites (fork) 
are as indicated. Contact residues broadly neutralizing antibodies to both linear and 
conformational epitopes are as listed. Residues that participate in CD81 binding are labeled 
in blue and glycosylation sites that affect antibody neutralization are in dark green. For the 
conformational epitopes, contact residues are located mainly at two discontinuous regions, 
aa424–443 and aa523–540. 
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Figure 2. Putative model of HCV E2 glycoprotein based on a class II fold with the 
expansion of Domain I and the contact residues recognized by broad neutralization 
antibody. The linear sequence of HCV H77-E2 ectodomain from aa384–715, is 
represented as a chain of beads (right) or schematic diagram of the tertiary organization 
(left), and the expanded DI is shown in the middle. For the model on the right, colored 
circles are labeled with the corresponding amino acid. Circles in pale and bright colors 
represent residues in the background and foreground of the domains, respectively labeled 
in white and black fonts. Residues that participate in CD81 binding are contoured in blue. 
Disulfide bonds and glycosylation sites are indicated by thick black bars and green circles, 
respectively, numbered sequentially. Unstructured segments are in white font on a brown 
background. For the left schematic diagram, DI, DII and DIII are labeled in red, yellow 
and blue, respectively. The connectivity of the β-strands in DI is indicated, labeled with the 
standard class II nomenclature. In the middle graph, the conserved epitopes recognized by 
broadly neutralization antibodies are labeled with yellow circle in the expanded DI. The 
residues recognized by linear epitope are outlined with bright purple, while conformational 
epitopes are outlined with dark purple. Residues that participate in CD81 binding are 
labeled in blue and glycosylation sites in dark green. Some of the residues are numbered as 
the amino acid position in the E2 glycoprotein. The specific contact residues for the 
conformational antibodies are located on four β-strands, C0, D0, E0 and F0, which form the 
top -sheet of domain I, overlapping with CD81 binding residues. Figure 2 is adapted with 
permission from Krey et al. [62]. 
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4. Neutralizing Antibodies to Conformational Epitopes  
The majority of antibodies with broad neutralizing activities recognized conformational epitopes on 
E2 [26,67–70]. In a panel of HCV HMAbs generated from peripheral B cells of patients with chronic 
HCV infection, cross-competition analyses delineated at least three immunogenic clusters of 
overlapping epitopes with distinct properties [71,72]. Non-neutralizing HMAbs fell within one cluster, 
which we have designated as “domain A”, while neutralizing HMAbs segregated into two clusters, 
designated as domain B and C. HMAbs to domain B display varying neutralizing activity against 
HCVpp containing glycoproteins of HCV genotypes 1 to 6, and some neutralizing all genotypes, such 
as the antibody designated as CBH-5 [73,74]. Although HC-1 has a broad neutralization profile, the 
potency against most HCV isolates was modest [73,74]. After affinity maturation by random 
mutagenesis on yeast surface display, affinity-matured HC-1 IgG clones showed improved neutralizing 
potency against a panel of genotype 1-5 HCVpp isolates and 2a HCVcc [75]. Of note, some of the 
affinity-matured antibodies neutralized a viral isolate that was not neutralized by wild-type HC-1 [75]. 
Alanine substitution studies revealed that two conserved E2 residues, G530 and D535, are required for 
binding of all domain B HMAbs, while G523 or W529 are required for some but not all of these 
antibodies [73,74]. Importantly, W529, G530 and D535 participate in the interaction of E2 with CD81. 
The data thus suggest that domain B HMAbs exert potent and broad neutralizing effects on HCV by 
competing with CD81 for binding to conserved residues on E2 that are important for viral entry. For 
certain domain B antibodies, including CBH-2 and HC-11, epitope mapping also revealed contact 
residues within the region encompassing aa425–443 (Figure 1) [76]. Residues within aa425–443 have 
been implicated in E2 binding to CD81 [77]. Consistent with this, studies by multiple groups on 
broadly neutralizing HMAbs isolated from combinatorial libraries also recognized epitopes containing 
these residues [26,78,79]. In one study, their antibodies were sorted into three groups, designated as 
AR1, AR2 and AR3, based on different binding patterns and competition with other defined 
monoclonal antibodies. While AR1 and AR2 antibodies, had limited breadth of neutralization, AR3 
antibodies showed broad neutralization against genotype 1-6 HCVpp. In addition, an AR3-specific 
antibody protected Alb-uPA/SCID mice against the diversity of HCV quasispecies in an infectious 
inoculum. Epitope mapping identified AR3 epitopes being formed by three discontinuous E2 
segments, aa394–424, aa437–447 and aa523–540. Alanine scanning revealed contact residues located 
at S424, G523, G530, D535, V538 and N540 (Figure 1) [80]. Broadly neutralizing HMAbs, including 
A8, 1:7, e137 and e20, reported by other group also mapped to the E2 segment, aa523–540, and 
identified the same conserved contact residues located at W529, G530 or D535 (Figure 1) [78,79,81].  
In addition, in the proposed model of the tertiary organization of HCV E2 [62], the residues in the 
CD81 binding site on HCV E2 lie in domain I, which is a -sandwich formed from the C0D0E0F0 (top) 
and the B0I0H0G0 (bottom) -sheets. The binding site of these antibodies maps to the exposed top 
-sheet (Figure 2). The -strands forming the top sheet are segregated into two contiguous sequences, 
aa418–444 for C0D0 and aa526–542 for E0F0. The location of the contact residues for each of the 
neutralizing antibodies to conformational epitopes are also on two discontinuous E2 segments 
encompassing aa425–443 and aa523–540 (Figure 1), which are respectively contained in C0D0 and 
E0F0, and are in in close proximity within the top -sheet. Thus, the location of these contact residues Viruses 2011, 3 
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provides support for the model and indicate that these antibodies bind to the same exposed tertiary 
structure on E2 that interacts with CD81 (Figure 2).  
Understanding the interaction between broadly neutralizing antibodies and their epitopes provides 
the basis for rational design of a preventive HCV vaccine. The successful isolation of these antibodies 
suggests that domain B is a highly immunogenic region on HCV E2 containing a cluster of 
overlapping epitopes that are able to induce potent neutralizing antibodies. This is supported by the 
observation that an HCVpp mutant with an alanine substitution at N532A exhibited greater sensitivity 
to neutralizing sera obtained from individuals infected with HCV genotype 1a, 1b, 2b, 3, 4 or 5 
viruses [82], which is consistent with these sera contain domain B-like antibodies directed at residues 
near N532. Two questions are of concern from a vaccine perspective: which of the domain B epitopes 
are prone to accumulating mutations under immune pressure, leading to virus escape from 
neutralization, as observed with the antibody response to HVR-1 and aa412–423; and, which domain B 
epitopes remain relatively invariant so as to accommodate the interactions of E2 with CD81 required 
for virus viability. CBH-2, HC-11 and HC-1 are representatives of antibodies to overlapping epitopes 
on E2 mediating neutralization by blocking virus binding to CD81 (Figure 1). In a study with an 
approach that allowed escape variants to be amplified and isolated under increasing concentrations of a 
neutralizing antibody, three escape patterns were observed with these antibodies. For CBH-2, escape 
mutants were isolated containing mutations at D431G or A439E [76]. The induction of the escape 
mutant at D431G under the selective pressure of CBH-2 mimics the previously observed naturally 
occurring variant at this site, D431E, that was not neutralized by this antibody [83]. Furthermore, the 
similarity of the replication rate of infectious CBH-2 escape HCVcc mutants to that of wt HCVcc 
suggests that escape from CBH-2-like antibodies does not compromise viral fitness. In the escape 
studies with HMAb HC-11, wt HCVcc was completely eliminated, and no escape mutants were 
generated under a starting antibody concentration of 100 μg/mL. However, under the condition of 
increasing antibody concentrations starting at 0.05 μg/mL, an escape mutant with a single substitution 
at L438F was observed when the antibody concentration reached 10 μg/mL. A mutant containing 
double substitutions, located at L438F and N434D, appeared after continuing passage of the virus at 
selection 10 μg/mL. Another mutant with double substitutions at L438F and T435A appeared when 
HC-11 was increased to 100 μg/mL. By gradually increasing the selection pressure by gradually 
increasing the concentration of the antibody, escape mutants were isolated that were not apparent when 
infectious virus encounters a high antibody concentration. The implication for vaccine design is a 
requirement for the immunogen, containing an HC-11-like epitope, to be able to elicit a sufficiently 
high titer antibody response to avoid virus escape. If the antibody response is of low titer, virus escape 
can occur. Nonetheless, the escape mutations resulted in a progressive decrease in viral fitness under 
the selective pressure of HC-11. Huh7.5 cells infected with L438F HC-11 escape mutant at a low 
multiplicity of infection (MOI = 0.01) yielded eight times less virus than wt HCVcc. The double 
substitution mutant, L438F and T435A, yielded 256 times less virus. For HC-1, the antibody at a 
critical concentration completely suppressed viral replication and no escape mutants were isolated. The 
location of the contact residues for HC-1 appears to be limited to a more invariant segment of E2 
encompassing aa523–540 that interacts with CD81. Collectively, these findings highlight the 
substantial challenges inherent in developing HCV vaccines, and show that an effective vaccine will Viruses 2011, 3 
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need to induce antibodies to intrinsically conserved epitopes in order to lessen the probability of 
virus escape. 
5. Negative Modulation of Neutralizing Antibodies  
In addition to genetic mutation escape strategy from neutralization, there are other evasion 
strategies to negatively modulate the neutralizing antibody response. Glycosylation of the virus 
envelope, non-neutralizing antibodies or virion-associated lipoproteins may interfere with antibody-
mediated neutralization by masking neutralizing epitopes or otherwise limiting access of neutralizing 
antibodies to their cognate epitopes [82,84,85]. Studies with HCVpp and HCVcc indicate that N-linked 
glycans at conserved Asn residues of the E2 protein hinder neutralizing activities of HCV-specific 
polyclonal sera, as well as neutralizing HMAbs [82,84,86]. The fine mapping of domain B HMAbs 
provides an exact explanation why specific N-glycan sites on E2 may modulate antibody-mediated 
neutralization [82,84]. The N-glycan at Asn532 sits in the middle of two critical contact residues for all 
domain B antibodies and is therefore capable of hindering antibody binding. The substitution of the 
N-glycan at residue 532 could lead to an improved HCV immunogen. For non-neutralizing antibodies, 
it has been proposed that a segment of E2 encompassing aa434–446 (epitope II) encodes a cluster of 
epitopes that are associated with non-neutralizing antibodies, and that these antibodies inhibit the 
neutralizing activities of antibodies directed at an adjacent E2 segment encompassing aa412–426 
(epitope I) [87,88]. Depletion of the epitope-II antibodies in polyclonal IgG preps led to increase 
neutralizing titers of these antibody preparations [88]. If this is the case, it provides a contributing 
factor in explaining the existence of viremia in the context of high neutralizing antibodies titers in 
chronic HCV infection. The circulating HCV virions in the blood of patients, associated with host 
lipoproteins and immunoglobulin in the form of lipo-viro-particles (LVP), are heterogeneous in 
density and infectivity. The LVP corresponding to low density fractions expressed high infectivity, 
which could be blocked by the anti-apolipoprotein B (Apo B) and E antibodies [89]. HCV envelope 
glycoproteins have the intrinsic capacity to utilize lipoprotein synthesis and assembly machinery, and 
HCV virions production is closely connected to lipid metabolism which could serve as an assembly 
platform [90–92]. The extent to which the association of HCV with lipoproteins may impede access to 
the virion surface by neutralizing antibodies is not clear. Infectious HCVcc particles can be readily 
precipitated with antibody to ApoB, but are nonetheless neutralized with virus-specific HMAbs [93]. 
In the presence of high density lipoprotein (HDL) or human serum, the neutralization by anti-E2 
neutralizing antibodies of HCVpp and HCVcc could be attenuated [94]. Of HCV particles recovered 
from the liver of an immunodeficient patient, only 27% of the E2 and 8.5% of RNA could be 
immunoprecipitated with AP33 [95]. In contrast, two of our domain B HMAbs precipitated 52–67% of 
total E2 and 19–24% of total RNA [95]. Clearly, not all neutralizing epitopes are masked by lipids, but 
better quantitation of this potential negative regulator of neutralizing activity will require additional 
studies of wild-type HCV. 
In addition to virus entry by receptor-mediated endocytosis, HCV has been reported to spread from 
cell-to-cell [96–100]. This process appears to be mediated by HCV receptor molecules, CD81, SR-B1, 
Claudin-1 and Occludin [96,98], although there is some controversy whether CD81 is involved in this 
process [97]. While initial studies showed that neutralizing antibodies do not inhibit cell-to-cell spread, Viruses 2011, 3 
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there is some evidence that antibodies to SR-B1 and to HVR1 do inhibit this route of transmission 
[96,98]. Moreover, a small molecule inhibitor of HCV entry that binds to the carboxy-terminal region 
of E2 also inhibits cell-to-cell spread [99]. Taken together, the implication is that some antibodies to 
E2 could be effective in blocking cell-to-cell spread.  
6. Conclusions  
These studies illustrate the complexity of the antibody response to HCV and the multiple aspects of 
the ability of the virus to escape from antibody-mediated virus neutralization. While candidate 
neutralizing antibodies to highly conserved conformational and linear epitopes have been identified, a 
greater understanding of the factors contributing to virus escape or interference with virus 
neutralization will be required to define those protective determinants most likely to provide broad 
protection. Additional studies will also be required on the possible role of lipoproteins in masking 
virion surface domains involved in virus entry, although current data suggest that a specific cluster of 
epitopes (designated domain B) on HCV E2 remains exposed on low density cell culture infectious 
HCV virions. The emergence of escape viral mutants may be slowed by the successful induction of 
neutralizing antibodies to multiple determinants in an HCV vaccine. The encouraging data from these 
studies proved the existence of broadly neutralization antibodies that are not associated with virus 
escape. The identification of conserved epitopes shared by broadly protective antibodies, especially 
those that lessen the probability of virus escape, suggest that active immunization strategies can in fact 
be a realistic goal.  
Acknowledgments 
We thank Felix Rey for critical comments. This work is supported in part by PHS grant AI081903 
and research support from Crucell NV to SKHF. 
Conflict of Interest 
The authors declare no conflict of interest. 
References and Notes 
1.  World Health Organization. Initiative for vaccine research. Hepatitis C. Available online: 
http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html (accessed on 12 
September 2011). 
2.  Shepard, C.W.; Finelli, L.; Alter, M.J. Global epidemiology of hepatitis C virus infection. 
Lancet Infect. Dis. 2005, 5, 558–567. 
3.  Pawlotsky, J.M. The results of Phase III clinical trials with telaprevir and boceprevir presented at 
the Liver Meeting 2010: A new standard of care for hepatitis C virus genotype 1 infection, but 
with issues still pending. Gastroenterology 2011, 140, 746–754. 
4.  Pawlotsky, J.M. Treatment failure and resistance with direct-acting antiviral drugs against 
hepatitis C virus. Hepatology 2011, 53, 1742–1751. Viruses 2011, 3 
 
2138
5.  Gerlach, J.T.; Diepolder, H.M.; Jung, M.C.; Gruener, N.H.; Schraut, W.W.; Zachoval, R.; 
Hoffmann, R.; Schirren, C.A.; Santantonio, T.; Pape, G.R. Recurrence of hepatitis C virus after 
loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 1999, 117, 
933–941. 
6.  Thimme, R.; Oldach, D.; Chang, K.M.; Steiger, C.; Ray, S.C.; Chisari, F.V. Determinants of viral 
clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 2001,  194,  
1395–1406. 
7.  Bowen, D.G.; Walker, C.M. Adaptive immune responses in acute and chronic hepatitis C virus 
infection. Nature 2005, 436, 946–952. 
8.  Knodell, R.G., Conrad, M. E., Ginsberg, A. L. and Bell, C. J. Efficacy of prophylactic   
gamma-globulin in preventing non-A, non-B post-transfection hepatitis. Lancet 1976, 1, 557–561. 
9.  Conrad, M.E.; Lemon, S.M. Prevention of endemic icteric viral hepatitis by administration of 
immune serum gamma globulin. J. Infect. Dis. 1987, 156, 56–63. 
10.  Sanchez-Quijano, A.; Pineda, J.A.; Lissen, E.; Leal, M.; Diaz-Torres, M.A.; Garcia De Pesquera, 
F.; Rivera, F.; Castro, R.; Munoz, J. Prevention of post-transfusion non-A, non-B hepatitis by 
non-specific immunoglobulin in heart surgery patients. Lancet 1988, 1, 1245–1249. 
11. Sugg, U.; Schneider, W.; Hoffmeister, H.E.; Huth, C.; Stephan, W.; Lissner, R.; Haase, W. 
Hepatitis B immune globulin to prevent non-A, non-B post-transfusion hepatitis. Lancet 1985, 1, 
405–406. 
12.  Piazza, M.; Sagliocca, L.; Tosone, G.; Guadagnino, V.; Stazi, M.A.; Orlando, R.; Borgia, G.; 
Rosa, D.; Abrignani, S.; Palumbo, F.; et al. Sexual transmission of the hepatitis C virus and 
efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial. 
Arch. Intern. Med. 1997, 157, 1537–1544. 
13.  Farci, P.; Alter, H.J.; Wong, D.C.; Miller, R.H.; Govindarajan, S.; Engle, R.; Shapiro, M.; Purcell, 
R.H. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro 
neutralization. Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 7792–7796. 
14.  Krawczynski, K.; Alter, M.J.; Tankersley, D.L.; Beach, M.; Robertson, B.H.; Lambert, S.; Kuo, 
G.; Spelbring, J.E.; Meeks, E.; Sinha, S.; et al. Effect of immune globulin on the prevention of 
experimental hepatitis C virus infection. J. Infect. Dis. 1996, 173, 822–828. 
15.  Bartosch, B.; Dubuisson, J.; Cosset, F.L. Infectious hepatitis C virus pseudo-particles containing 
functional E1-E2 envelope protein complexes. J. Exp. Med. 2003, 197, 633–642. 
16.  Hsu, M.; Zhang, J.; Flint, M.; Logvinoff, C.; Cheng-Mayer, C.; Rice, C.M.; McKeating, J.A. 
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral 
particles. Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 7271–7276. 
17.  Cai, Z.; Zhang, C.; Chang, K.S.; Jiang, J.; Ahn, B.C.; Wakita, T.; Liang, T.J.; Luo, G. Robust 
production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human 
hepatoma cells. J. Virol. 2005, 79, 13963–13973. 
18. Zhong, J.; Gastaminza, P.; Cheng, G.; Kapadia, S.; Kato, T.; Burton, D.R.; Wieland, S.F.; 
Uprichard, S.L.; Wakita, T.; Chisari, F.V. Robust hepatitis C virus infection in vitro. Proc. Natl. 
Acad. Sci. U. S. A. 2005, 102, 9294–9299. Viruses 2011, 3 
 
2139
19. Wakita, T.; Pietschmann, T.; Kato, T.; Date, T.; Miyamoto, M.; Zhao, Z.; Murthy, K.; Habermann, 
A.; Krausslich, H.G.; Mizokami, M.; et al. Production of infectious hepatitis C virus in tissue 
culture from a cloned viral genome. Nat. Med. 2005, 11, 791–796. 
20.  Bartosch, B.; Bukh, J.; Meunier, J.C.; Granier, C.; Engle, R.E.; Blackwelder, W.C.; Emerson, 
S.U.; Cosset, F.L.; Purcell, R.H. In vitro assay for neutralizing antibody to hepatitis C virus:  
Evidence for broadly conserved neutralization epitopes. Proc. Natl. Acad. Sci. U. S. A. 2003, 100,  
14199–14204. 
21.  Lavillette, D.; Morice, Y.; Germanidis, G.; Donot, P.; Soulier, A.; Pagkalos, E.; Sakellariou, G.; 
Intrator, L.; Bartosch, B.; Pawlotsky, J.M.; et al. Human serum facilitates hepatitis C virus 
infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute 
phase of hepatitis C virus infection. J. Virol. 2005, 79, 6023–6034. 
22.  Pestka, J.M.; Zeisel, M.B.; Blaser, E.; Schurmann, P.; Bartosch, B.; Cosset, F.L.; Patel, A.H.; 
Meisel, H.; Baumert, J.; Viazov, S.; et al. Rapid induction of virus-neutralizing antibodies and 
viral clearance in a single-source outbreak of hepatitis C. Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 
6025–6030. 
23.  Fafi-Kremer, S.; Fofana, I.; Soulier, E.; Carolla, P.; Meuleman, P.; Leroux-Roels, G.; Patel, A.H.; 
Cosset, F.L.; Pessaux, P.; Doffoel, M.; et al. Viral entry and escape from antibody-mediated 
neutralization influence hepatitis C virus reinfection in liver transplantation. J. Exp. Med. 2010, 
207, 2019–2031. 
24.  Mercer, D.F.; Schiller, D.E.; Elliott, J.F.; Douglas, D.N.; Hao, C.; Rinfret, A.; Addison, W.R.; 
Fischer, K.P.; Churchill, T.A.; Lakey, J.R.; et al. Hepatitis C virus replication in mice with 
chimeric human livers. Nat. Med. 2001, 7, 927–933. 
25. Vanwolleghem, T.; Bukh, J.; Meuleman, P.; Desombere, I.; Meunier, J.C.; Alter, H.; Purcell, R.H.; 
Leroux-Roels, G. Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect 
human liver-chimeric mice from infection with a homologous hepatitis C virus strain. Hepatology 
2008, 47, 1846–1855. 
26.  Law, M.; Maruyama, T.; Lewis, J.; Giang, E.; Tarr, A.W.; Stamataki, Z.; Gastaminza, P.; Chisari, 
F.V.; Jones, J.M.; Fox, R.; et al. Broadly neutralizing antibodies protect against hepatitis C virus 
quasispecies challenge. Nat. Med. 2008, 14, 25–27. 
27.  Dorner, M.; Horwitz, J.A.; Robbins, J.B.; Barry, W.T.; Feng, Q.; Mu, K.; Jones, C.T.; Schoggins, 
J.W.; Catanese, M.T.; Burton, D.R.; et al. A genetically humanized mouse model for hepatitis C 
virus infection. Nature 2011, 474, 208–211. 
28.  Meunier, J.C.; Russell, R.S.; Goossens, V.; Priem, S.; Walter, H.; Depla, E.; Union, A.; Faulk, 
K.N.; Bukh, J.; Emerson, S.U.; et al. Isolation and characterization of broadly neutralizing human 
monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. J. Virol. 2008, 82, 966–973. 
29. Pietschmann, T.; Kaul, A.; Koutsoudakis, G.; Shavinskaya, A.; Kallis, S.; Steinmann, E.; Abid, K.; 
Negro, F.; Dreux, M.; Cosset, F.L.; et al. Construction and characterization of infectious 
intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl. Acad. Sci. U. S. A. 2006, 
103, 7408–7413. Viruses 2011, 3 
 
2140
30. Rollier, C.; Depla, E.; Drexhage, J.A.R.; Verschoor, E.J.; Verstrepen, B.E.; Fatmi, A.; Brinster, C.; 
Fournillier, A.; Whelan, J.A.; Whelan, M.; et al. Control of heterologous hepatitis C virus 
Infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper 
immune response. J. Virol. 2004, 78, 187–196. 
31.  Benedicto, I.; Molina-Jimenez, F.; Barreiro, O.; Maldonado-Rodriguez, A.; Prieto, J.; Moreno-
Otero, R.; Aldabe, R.; Lopez-Cabrera, M.; Majano, P.L. Hepatitis C virus envelope components 
alter localization of hepatocyte tight junction-associated proteins and promote occludin retention 
in the endoplasmic reticulum. Hepatology 2008, 48, 1044–1053. 
32.  Benedicto, I.; Molina-Jimenez, F.; Bartosch, B.; Cosset, F.L.; Lavillette, D.; Prieto, J.; Moreno-
Otero, R.; Valenzuela-Fernandez, A.; Aldabe, R.; Lopez-Cabrera, M.; et al. Tight junction-
associated protein occludin is required for a post-binding step in hepatitis C virus entry and 
infection. J. Virol. 2009, 83, 8012–8020. 
33.  Evans, M.J.; von Hahn, T.; Tscherne, D.M.; Syder, A.J.; Panis, M.; Wolk, B.; Hatziioannou, T.; 
McKeating, J.A.; Bieniasz, P.D.; Rice, C.M. Claudin-1 is a hepatitis C virus co-receptor required 
for a late step in entry. Nature 2007, 446, 801–805. 
34.  Liu, S.; Yang, W.; Shen, L.; Turner, J.R.; Coyne, C.B.; Wang, T. Tight junction proteins claudin-
1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent 
superinfection. J. Virol. 2009, 83, 2011–2014. 
35.  Meertens, L.; Bertaux, C.; Cukierman, L.; Cormier, E.; Lavillette, D.; Cosset, F.L.; Dragic, T. The 
tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virus. J. Virol. 2008, 
82, 3555–3560. 
36.  Ploss, A.; Evans, M.J.; Gaysinskaya, V.A.; Panis, M.; You, H.; de Jong, Y.P.; Rice, C.M. Human 
occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009, 457, 
882–886. 
37. Pileri, P.; Uematsu, Y.; Campagnoli, S.; Galli, G.; Falugi, F.; Petracca, R.; Weiner, A.J.; 
Houghton, M.; Rosa, D.; Grandi, G.; et al. Binding of hepatitis C virus to CD81. Science 1998, 
282, 938–941. 
38.  Scarselli, E.; Ansuini, H.; Cerino, R.; Roccasecca, R.M.; Acali, S.; Filocamo, G.; Traboni, C.; 
Nicosia, A.; Cortese, R.; Vitelli, A. The human scavenger receptor class B type I is a novel 
candidate receptor for the hepatitis C virus. EMBO J. 2002, 21, 5017–5025. 
39.  Shimizu, Y.K.; Hijikata, M.; Iwamoto, A.; Alter, H.J.; Purcell, R.H.; Yoshikura, H. Neutralizing 
antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. 
J. Virol. 1994, 68, 1494–1500. 
40. Zibert, A.; Schreier, E.; Roggendorf, M. Antibodies in human sera specific to hypervariable 
region 1 of hepatitis C virus can block viral attachment. Virology 1995, 208, 653–661. 
41.  Zibert, A.; Dudziak, P.; Schreier, E.; Roggendorf, M. Characterization of antibody response to 
hepatitis C virus protein E2 and significance of hypervariable region 1-specific antibodies in viral 
neutralization. Arch. Virol. 1997, 142, 523–534. 
42.  Ray, R.; Meyer, K.; Banerjee, A.; Basu, A.; Coates, S.; Abrignani, S.; Houghton, M.; Frey, S.E.; 
Belshe, R.B. Characterization of antibodies induced by vaccination with hepatitis C virus 
envelope glycoproteins. J. Infect. Dis. 2010, 202, 862–866. Viruses 2011, 3 
 
2141
43. Zucchelli, S.; Roccasecca, R.; Meola, A.; Ercole, B.B.; Tafi, R.; Dubuisson, J.; Galfre, G.; Cortese, 
R.; Nicosia, A. Mimotopes of the hepatitis C virus hypervariable region 1, but not the natural 
sequences, induce cross-reactive antibody response by genetic immunization. Hepatology 2001, 
33, 692–703. 
44.  Shimizu, Y.K.; Igarashi, H.; Kiyohara, T.; Cabezon, T.; Farci, P.; Purcell, R.H.; Yoshikura, H. A 
hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of 
hepatitis C virus can prevent viral infection in cell cultures. Virology 1996, 223, 409–412. 
45. Esumi, M.; Rikihisa, T.; Nishimura, S.; Goto, J.; Mizuno, K.; Zhou, Y.H.; Shikata, T. 
Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 
1 peptides of hepatitis C virus in chimpanzees. Arch. Virol. 1999, 144, 973–980. 
46.  Farci, P.; Shimoda, A.; Wong, D.; Cabezon, T.; De Gioannis, D.; Strazzera, A.; Shimizu, Y.; 
Shapiro, M.; Alter, H.J.; Purcell, R.H. Prevention of hepatitis C virus infection in chimpanzees by 
hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc. Natl. 
Acad. Sci. U. S. A. 1996, 93, 15394–15399. 
47.  Goto, J.; Nishimura, S.; Esumi, M.; Makizumi, K.; Rikihisa, T.; Nishihara, T.; Mizuno, K.; Zhou, 
Y.; Shikata, T.; Fujiyama, S.; et al. Prevention of hepatitis C virus infection in a chimpanzee by 
vaccination and epitope mapping of antiserum directed against hypervariable region 1. 
Hepatol. Res. 2001, 19, 270–283. 
48.  Kato, N.; Sekiya, H.; Ootsuyama, Y.; Nakazawa, T.; Hijikata, M.; Ohkoshi, S.; Shimotohno, K. 
Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) 
of hepatitis C virus. J. Virol. 1993, 67, 3923–3930. 
49.  Weiner, A.J.; Geysen, H.M.; Christopherson, C.; Hall, J.E.; Mason, T.J.; Saracco, G.; Bonino, F.; 
Crawford, K.; Marion, C.D.; Crawford, K.A.; et al. Evidence for immune selection of hepatitis C 
virus (HCV) putative envelope glycoprotein variants: Potential role in chronic HCV infections. 
Proc. Natl. Acad. Sci. U. S. A. 1992, 89, 3468–3472. 
50.  von Hahn, T.; Yoon, J.C.; Alter, H.; Rice, C.M.; Rehermann, B.; Balfe, P.; McKeating, J.A. 
Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during 
chronic infection in vivo. Gastroenterology 2007, 132, 667–678. 
51. Dowd, K.A.; Netski, D.M.; Wang, X.H.; Cox, A.L.; Ray, S.C. Selection pressure from 
neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. 
Gastroenterology 2009, 136, 2377–2386. 
52.  Zhang, X.X.; Deng, Q.; Zhang, S.Y.; Liu, J.; Cai, Q.; Lu, Z.M.; Wang, Y. Broadly cross-reactive 
mimotope of hypervariable region 1 of hepatitis C virus derived from DNA shuffling and 
screened by phage display library. J. Med. Virol. 2003, 71, 511–517. 
53. Puntoriero, G.; Meola, A.; Lahm, A.; Zucchelli, S.; Ercole, B.B.; Tafi, R.; Pezzanera, M.; 
Mondelli, M.U.; Cortese, R.; Tramontano, A.; et al. Towards a solution for hepatitis C virus 
hypervariability: Mimotopes of the hypervariable region 1 can induce antibodies cross-reacting 
with a large number of viral variants. EMBO J. 1998, 17, 3521–3533. 
54.  Prentoe, J.; Jensen, T.B.; Meuleman, P.; Serre, S.B.; Scheel, T.K.; Leroux-Roels, G.; Gottwein, 
J.M.; Bukh, J. Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of 
genotypes 1 to 6 and impairs virus neutralization. J. Virol. 2011, 85, 2224–2234. Viruses 2011, 3 
 
2142
55.  Bankwitz, D.; Steinmann, E.; Bitzegeio, J.; Ciesek, S.; Friesland, M.; Herrmann, E.; Zeisel, M.B.; 
Baumert, T.F.; Keck, Z.Y.; Foung, S.K.; et al. Hepatitis C virus hypervariable region 1 modulates 
receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing 
epitopes. J. Virol. 2010, 84, 5751–5763. 
56.  Owsianka, A.; Tarr, A.W.; Juttla, V.S.; Lavillette, D.; Bartosch, B.; Cosset, F.L.; Ball, J.K.; Patel, 
A.H. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus 
E2 envelope glycoprotein. J. Virol. 2005, 79, 11095–11104. 
57. Tarr, A.W.; Owsianka, A.M.; Timms, J.M.; McClure, C.P.; Brown, R.J.; Hickling, T.P.; 
Pietschmann, T.; Bartenschlager, R.; Patel, A.H.; Ball, J.K. Characterization of the hepatitis C 
virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology 
2006, 43, 592–601. 
58.  Broering, T.J.; Garrity, K.A.; Boatright, N.K.; Sloan, S.E.; Sandor, F.; Thomas, W.D., Jr.; Szabo, 
G.; Finberg, R.W.; Ambrosino, D.M.; Babcock, G.J. Identification and characterization of broadly 
neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of 
hepatitis C virus. J. Virol. 2009, 83, 12473–12482. 
59.  Flint, M.; Maidens, C.; Loomis-Price, L.D.; Shotton, C.; Dubuisson, J.; Monk, P.; Higginbottom, 
A.; Levy, S.; McKeating, J.A. Characterization of hepatitis C virus E2 glycoprotein interaction 
with a putative cellular receptor, CD81. J. Virol. 1999, 73, 6235–6244. 
60. Owsianka, A.M.; Timms, J.M.; Tarr, A.W.; Brown, R.J.; Hickling, T.P.; Szwejk, A.; 
Bienkowska-Szewczyk, K.; Thomson, B.J.; Patel, A.H.; Ball, J.K. Identification of conserved 
residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. 
J. Virol. 2006, 80, 8695–8704. 
61.  Sabo, M.C.; Luca, V.C.; Prentoe, J.; Hopcraft, S.E.; Blight, K.J.; Yi, M.; Lemon, S.M.; Ball, J.K.; 
Bukh, J.; Evans, M.J.; et al. Neutralizing monoclonal antibodies against hepatitis C virus E2 
protein bind discontinuous epitopes and inhibit infection at a postattachment step. J. Virol. 2011, 
85, 7005–7019. 
62.  Krey, T.; d'Alayer, J.; Kikuti, C.M.; Saulnier, A.; Damier-Piolle, L.; Petitpas, I.; Johansson, D.X.; 
Tawar, R.G.; Baron, B.; Robert, B.; et al. The disulfide bonds in glycoprotein E2 of hepatitis C 
virus reveal the tertiary organization of the molecule. PLoS Pathog. 2010, 6, e1000762. 
63.  Rey, F.A.; Heinz, F.X.; Mandl, C.; Kunz, C.; Harrison, S.C. The envelope glycoprotein from tick-
borne encephalitis virus at 2 A resolution. Nature 1995, 375, 291–298. 
64.  Gal-Tanamy, M.; Keck, Z.; Yi, M.; McKeating, J.; Patel, A.H.; Foung, S.K.; Lemon, M.K. In 
vitro selection of a neutralization-resistant hepatitis C virus escape mutant. Proc. Natl. Acad. Sci. 
U. S. A. 2008, 105 19450–19455. 
65.  Tarr, A.W.; Owsianka, A.M.; Jayaraj, D.; Brown, R.J.; Hickling, T.P.; Irving, W.L.; Patel, A.H.; 
Ball, J.K. Determination of the human antibody response to the epitope defined by the hepatitis C 
virus-neutralizing monoclonal antibody AP33. J. Gen. Virol. 2007, 88, 2991–3001. 
66. Dhillon, S.; Witteveldt, J.; Gatherer, D.; Owsianka, A.M.; Zeisel, M.B.; Zahid, M.N.; Rychlowska, 
M.; Foung, S.K.; Baumert, T.F.; Angus, A.G.; et al. Mutations within a conserved region of the 
hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to 
neutralizing antibodies. J. Virol. 2010, 84, 5494–5507. Viruses 2011, 3 
 
2143
67.  Hadlock, K.G.; Lanford, R.E.; Perkins, S.; Rowe, J.; Yang, Q.; Levy, S.; Pileri, P.; Abrignani, S.; 
Foung, S.K. Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to 
CD81 and recognize conserved conformational epitopes. J. Virol. 2000, 74, 10407–10416. 
68.  Allander, T.; Drakenberg, K.; Beyene, A.; Rosa, D.; Abrignani, S.; Houghton, M.; Widell, A.; 
Grillner, L.; Persson, M.A. Recombinant human monoclonal antibodies against different 
conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its 
interaction with CD81. J. Gen. Virol. 2000, 81, 2451–2459. 
69. Bugli, F.; Mancini, N.; Kang, C.Y.; Di Campli, C.; Grieco, A.; Manzin, A.; Gabrielli, A.; 
Gasbarrini, A.; Fadda, G.; Varaldo, P.E.; et al. Mapping B-cell epitopes of hepatitis C virus E2 
glycoprotein using human monoclonal antibodies from phage display libraries. J. Virol. 2001, 75, 
9986–9990. 
70.  Habersetzer, F.; Fournillier, A.; Dubuisson, J.; Rosa, D.; Abrignani, S.; Wychowski, C.; Nakano, 
I.; Trepo, C.; Desgranges, C.; Inchauspe, G. Characterization of human monoclonal antibodies 
specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties. 
Virology 1998, 249, 32–41. 
71.  Keck, Z.Y.; Op De Beeck, A.; Hadlock, K.G.; Xia, J.; Li, T.K.; Dubuisson, J.; Foung, S.K. 
Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with 
distinct properties and biological functions. J. Virol. 2004, 78, 9224–9232. 
72.  Keck, Z.Y.; Li, T.K.; Xia, J.; Bartosch, B.; Cosset, F.L.; Dubuisson, J.; Foung, S.K. Analysis of a 
highly flexible conformational immunogenic domain a in hepatitis C virus E2. J. Virol. 2005, 79, 
13199–13208. 
73. Keck, Z.Y.; Li, T.K.; Xia, J.; Gal-Tanamy, M.; Olson, O.; Li, S.H.; Patel, A.H.; Ball, J.K.; Lemon, 
S.M.; Foung, S.K. Definition of a conserved immunodominant domain on hepatitis C virus E2 
glycoprotein by neutralizing human monoclonal antibodies. J. Virol. 2008, 82, 6061–6066. 
74.  Owsianka, A.M.; Tarr, A.W.; Keck, Z.; Li, T.; Witteveldt, J.; Adair, R.; Foung, S.; Ball, J.K.; 
Patel, A.H. Broadly neutralizing human monoclonal antibodies to Hepatitis C Virus E2 
glycoprotein. J. Gen. Virol. 2008, 89, 653–659. 
75.  Wang, Y.; Keck, Z.; Saha, A.; Xia, J.; Conrad, F.; Lou, J.; Eckart, M.; Marks, J.D.; Foung, S. 
Affinity maturation to improve human monoclonal antibody neutralization potency and breadth of 
reactivity against hepatitis C virus. J. Biol. Chem. 2011, doi:10.1074/jbc.M1111.290783. 
76.  Keck, Z.Y.; Saha, A.; Xia, J.; Wang, Y.; Lau, P.; Krey, T.; Rey, F.A.; Foung, S.K. Mapping a 
region of HCV E2 that is responsible for escape from neutralizing antibodies and a core   
CD81-binding region that does not tolerate neutralization escape mutations. J. Virol. 2011, 85,  
10451–10463. 
77.  Drummer, H.E.; Boo, I.; Maerz, A.L.; Poumbourios, P. A conserved Gly436-Trp-Leu-Ala-Gly-
Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and 
viral entry. J. Virol. 2006, 80, 7844–7853. 
78.  Johansson, D.X.; Voisset, C.; Tarr, A.W.; Aung, M.; Ball, J.K.; Dubuisson, J.; Persson, M.A. 
Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. 
Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 16269–16274. Viruses 2011, 3 
 
2144
79. Perotti, M.; Mancini, N.; Diotti, R.A.; Tarr, A.W.; Ball, J.K.; Owsianka, A.; Adair, R.; Patel, A.H.; 
Clementi, M.; Burioni, R. Identification of a broadly cross-reacting and neutralizing human 
monoclonal antibody directed against the hepatitis C virus E2 protein. J. Virol. 2008,  82,  
1047–1052. 
80.  Law, M.; Maruyama, T.; Lewis, J.; Giang, E.; Tarr, A.W.; Stamataki, Z.; Gastaminza, P.; Chisari, 
F.V.; Jones, I.M.; Fox, R.I.; et al. Broadly neutralizing antibodies protect against hepatitis C virus 
quasispecies challenge. Nat. Med. 2008, 14, 25–27. 
81.  Mancini, N.; Diotti, R.A.; Perotti, M.; Sautto, G.; Clementi, N.; Nitti, G.; Patel, A.H.; Ball, J.K.; 
Clementi, M.; Burioni, R. Hepatitis C virus (HCV) infection may elicit neutralizing antibodies 
targeting epitopes conserved in all viral genotypes. PLoS One 2009, 4, e8254. 
82.  Helle, F.; Goffard, A.; Morel, V.; Duverlie, G.; McKeating, J.; Keck, Z.Y.; Foung, S.; Penin, F.; 
Dubuisson, J.; Voisset, C. The neutralizing activity of anti-hepatitis C virus antibodies is 
modulated by specific glycans on the E2 envelope protein. J. Virol. 2007, 81, 8101–8111. 
83.  Keck, Z.Y.; Olson, O.; Gal-Tanamy, M.; Xia, J.; Patel, A.H.; Dreux, M.; Cosset, F.L.; Lemon, 
S.M.; Foung, S.K. A point mutation leading to hepatitis C virus escape from neutralization by a 
monoclonal antibody to a conserved conformational epitope. J. Virol. 2008, 82, 6067–6072. 
84. Falkowska, E.; Kajumo, F.; Garcia, E.; Reinus, J.; Dragic, T. Hepatitis C virus envelope 
glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization. J. Virol. 2007, 81, 
8072–8079. 
85. Thomssen, R.; Bonk, S.; Propfe, C.; Heermann, K.H.; Kochel, H.G.; Uy, A. Association of 
hepatitis C virus in human sera with beta-lipoprotein. Med. Microbiol. Immunol. (Berl.) 1992, 181, 
293–300. 
86.  Helle, F.; Vieyres, G.; Elkrief, L.; Popescu, C.I.; Wychowski, C.; Descamps, V.; Castelain, S.; 
Roingeard, P.; Duverlie, G.; Dubuisson, J. Role of N-linked glycans in the functions of hepatitis C 
virus envelope proteins incorporated into infectious virions. J. Virol. 2010, 84, 11905–11915. 
87.  Zhang, P.; Wu, C.G.; Mihalik, K.; Virata-Theimer, M.L.; Yu, M.Y.; Alter, H.J.; Feinstone, S.M. 
Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. 
Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 8449–8454. 
88.  Zhang, P.; Zhong, L.; Struble, E.B.; Watanabe, H.; Kachko, A.; Mihalik, K.; Virata-Theimer, 
M.L.; Alter, H.J.; Feinstone, S.; Major, M. Depletion of interfering antibodies in chronic hepatitis 
C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc. 
Natl. Acad. Sci. U. S. A. 2009, 106, 7537–7541. 
89.  Andre, P.; Komurian-Pradel, F.; Deforges, S.; Perret, M.; Berland, J.L.; Sodoyer, M.; Pol, S.; 
Brechot, C.; Paranhos-Baccala, G.; Lotteau, V. Characterization of low- and very-low-density 
hepatitis C virus RNA-containing particles. J. Virol. 2002, 76, 6919–6928. 
90.  Icard, V.; Diaz, O.; Scholtes, C.; Perrin-Cocon, L.; Ramiere, C.; Bartenschlager, R.; Penin, F.; 
Lotteau, V.; Andre, P. Secretion of hepatitis C virus envelope glycoproteins depends on assembly 
of apolipoprotein B positive lipoproteins. PLoS One 2009, 4, e4233. 
91.  Chang, K.S.; Jiang, J.; Cai, Z.; Luo, G. Human apolipoprotein e is required for infectivity and 
production of hepatitis C virus in cell culture. J. Virol. 2007, 81, 13783–13793. Viruses 2011, 3 
 
2145
92. Huang, H.; Sun, F.; Owen, D.M.; Li, W.; Chen, Y.; Gale, M., Jr.; Ye, J. Hepatitis C virus 
production by human hepatocytes dependent on assembly and secretion of very low-density 
lipoproteins. Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 5848–5853. 
93.  Yi, M., Y. Ma, J. Yates, and S. M. Lemon. Compensatory mutations in E1, p7, NS2 and NS3 
enhance yields of cell culture-infectious inter-genotypic chimeric hepatitis C virus. J. Virol. 2007, 
81, 629–638. 
94.  Dreux, M.; Pietschmann, T.; Granier, C.; Voisset, C.; Ricard-Blum, S.; Mangeot, P.E.; Keck, Z.; 
Foung, S.; Vu-Dac, N.; Dubuisson, J.; et al. High density lipoprotein inhibits hepatitis C   
virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. 
J. Biol. Chem. 2006, 281, 18285–18295. 
95. Nielsen, S.U.; Bassendine, M.F.; Burt, A.D.; Martin, C.; Pumeechockchai, W.; Toms, G.L. 
Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in 
iodixanol density gradients. J. Virol. 2006, 80, 2418–2428. 
96.  Timpe, J.M.; Stamataki, Z.; Jennings, A.; Hu, K.; Farquhar, M.J.; Harris, H.J.; Schwarz, A.; 
Desombere, I.; Roels, G.L.; Balfe, P.; et al. Hepatitis C virus cell-cell transmission in hepatoma 
cells in the presence of neutralizing antibodies. Hepatology 2008, 47, 17–24. 
97.  Witteveldt, J.; Evans, M.J.; Bitzegeio, J.; Koutsoudakis, G.; Owsianka, A.M.; Angus, A.G.; Keck, 
Z.Y.; Foung, S.K.; Pietschmann, T.; Rice, C.M.; et al. CD81 is dispensable for hepatitis C virus 
cell-to-cell transmission in hepatoma cells. J. Gen. Virol. 2009, 90, 48–58. 
98.  Brimacombe, C.L.; Grove, J.; Meredith, L.W.; Hu, K.; Syder, A.J.; Flores, M.V.; Timpe, J.M.; 
Krieger, S.E.; Baumert, T.F.; Tellinghuisen, T.L.; et al. Neutralizing antibody-resistant hepatitis C 
virus cell-to-cell transmission. J. Virol. 2011, 85, 596–605. 
99.  Baldick, C.J.; Wichroski, M.J.; Pendri, A.; Walsh, A.W.; Fang, J.; Mazzucco, C.E.; Pokornowski, 
K.A.; Rose, R.E.; Eggers, B.J.; Hsu, M.; et al. A novel small molecule inhibitor of hepatitis C 
virus entry. PLoS Pathog. 2010, 6, e1001086. 
100.  Valli, M.B.; Serafino, A.; Crema, A.; Bertolini, L.; Manzin, A.; Lanzilli, G.; Bosman, C.; 
Iacovacci, S.; Giunta, S.; Ponzetto, A.; et al. Transmission in vitro of hepatitis C virus from 
persistently infected human B-cells to hepatoma cells by cell-to-cell contact. J. Med. Virol. 2006, 
78, 192–201. 
© 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 